ACON

Aclarion Inc

3.09

Jul 02 • 04:00PM ET +0.07 (2.32%)

Healthcare Health Information Services USA Nano NASD

Peers: BFRG HCTI MGRX VSEE ZCMD MNDR BEAT DRIO FORA ONMD

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	7.61M
Enterprise Value	-11.42M
Income	-8.05M
Sales	0.08M
Book/sh	8.04
Cash/sh	7.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	11
IPO	Apr 22, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	95.12
P/B	0.38
P/C	0.40
P/FCF	-
EV/EBITDA	-
EV/Sales	-142.75
Quick Ratio	19.65
Current Ratio	19.65
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-9.23
EPS next Y	-5.37
EPS next Q	-1.05
EPS this Y	66.96%
EPS next Y	-19.07%
EPS next 5Y	-
EPS past 3/5Y	95.75% 83.48%
Sales past 3/5Y	7.80% 9.25%
EPS Y/Y TTM	99.78%
Sales Y/Y TTM	42.63%
EPS Q/Q	85.62%
Sales Q/Q	11.32%
Earnings	Jun 03
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	27.01%
Insider Trans	2.47%
Inst Own	4.57%
Inst Trans	13.49%
ROA	-43.37%
ROE	-45.43%
ROIC	-40.96%
Gross Margin	-280.02%
Oper. Margin	-10975.10%
Profit Margin	-10336.12%
SMA20	0.45%
SMA50	-3.27%
SMA200	-34.88%
Trades

Shs Outstand	2.44M
Shs Float	1.80M
Short Float	7.01%
Short Ratio	1.19
Short Interest	0.13M
52W High	12.03 -74.31%
52W Low	2.34 32.05%
Volatility	5.96% 6.32%
ATR (14)	0.19
RSI (14)	50.80
Beta	1.18
Rel Volume	0.20
Avg Volume	106.32K
Volume	21,252

Perf Week	14.02%
Perf Month	-11.71%
Perf Quarter	-9.38%
Perf Half Y	-30.72%
Perf YTD	-32.83%
Perf Year	-59.79%
Perf 3Y	-100.00%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	7.50
Prev Close	3.02
Price	3.09
Change	2.32%

Jun-10-26 07:00AM	Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub (GlobeNewswire)
Jun-09-26 07:00AM	Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform (GlobeNewswire)
Jun-08-26 07:05AM	Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal (GlobeNewswire) -5.88%
07:00AM	Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting (GlobeNewswire)
Jun-03-26 06:00AM	Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation (GlobeNewswire)
06:00AM	Loading…
Jun-01-26 06:00AM	Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study (GlobeNewswire)
May-28-26 02:49PM	Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal (GlobeNewswire)
08:00AM	Echo Lake Capital Offers To Acquire Aclarion Inc. (ACCESSWIRE)
May-07-26 06:00AM	Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment (GlobeNewswire)
May-06-26 06:00AM	Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. (GlobeNewswire)
May-05-26 06:00AM	Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine (GlobeNewswire)
Apr-30-26 06:00AM	Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption (GlobeNewswire)
Apr-28-26 06:00AM	Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan (GlobeNewswire)
Apr-22-26 08:30AM	Aclarion Announces $2.5 Million Stock Repurchase Plan (GlobeNewswire) +5.67%
Apr-16-26 06:47AM	Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain (GlobeNewswire)
08:00AM	Loading…
Apr-14-26 08:00AM	Aclarion Receives Pinnacle Award for AI Innovation (GlobeNewswire)
Apr-08-26 08:00AM	Aclarion Announces Agreement with Weill Cornell Medicine (GlobeNewswire)
Apr-07-26 08:00AM	Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video (GlobeNewswire)
Mar-24-26 08:00AM	Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc. (ACCESSWIRE) +10.58%
Mar-19-26 09:25AM	Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
06:00AM	Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts (GlobeNewswire)
Mar-17-26 06:00AM	Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet (GlobeNewswire)
Mar-12-26 06:00AM	Aclarion CEO Brent Ness to Attend LSI USA 2026 (GlobeNewswire)
Feb-05-26 06:00AM	Aclarion Publishes 2026 Shareholder Letter from the Chairman (GlobeNewswire) -12.59%
Feb-03-26 06:00AM	Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation (GlobeNewswire)
Jan-13-26 10:51AM	Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout (Benzinga) -6.87%
06:00AM	Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 (GlobeNewswire)
Jan-08-26 08:29AM	Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars (Benzinga) +42.09%
06:00AM	Aclarion Provides 2025 Update and 2026 Corporate Outlook (GlobeNewswire)
Jan-06-26 06:00AM	Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data (GlobeNewswire)
08:00AM	Loading…
Dec-04-25 08:00AM	Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) (GlobeNewswire) +5.55%
Dec-02-25 08:00AM	Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S. (GlobeNewswire) +10.31%
Nov-05-25 06:00AM	Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion (GlobeNewswire)
Oct-22-25 06:00AM	Aclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH (GlobeNewswire)
Oct-14-25 06:09AM	Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst (GlobeNewswire) -7.64%
Oct-13-25 06:00AM	Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference (GlobeNewswire) +12.71%
Oct-09-25 06:00AM	Aclarion to Present at the LD Micro Main Event XIX (Newsfile) -5.39%
Oct-07-25 06:00AM	Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH (GlobeNewswire)
Oct-01-25 07:17AM	Aclarion Presents at LSI Europe '25 Highlighting Nociscan Technology and Key Value Drivers (GlobeNewswire)
Sep-25-25 06:00AM	First Patients Enrolled at UHealth - University of Miami in Aclarion's Pivotal CLARITY Trial (GlobeNewswire)
Sep-03-25 06:00AM	Aclarion Appoints Greg Gould as Chief Financial Officer (GlobeNewswire)
Aug-07-25 06:05PM	AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-05-25 06:00AM	Auddia Announces Non-binding Letter of Intent for Business Combination and Restructuring (GlobeNewswire) +5.71%
06:00AM	Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts (GlobeNewswire)
Jul-07-25 04:01PM	Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders (GlobeNewswire)
Jun-25-25 06:00AM	First Patient Enrolled in Aclarion's Groundbreaking CLARITY Trial (GlobeNewswire)
Jun-24-25 07:00AM	Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum (GlobeNewswire)
Jun-10-25 06:00AM	Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site (GlobeNewswire)
May-20-25 06:00AM	Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site (GlobeNewswire)
May-12-25 07:34AM	Aclarion Announces Texas Back Institute as New CLARITY Trial Site (GlobeNewswire) +7.04%
May-05-25 06:00AM	Aclarion Welcomes Advocate Health as CLARITY Trial Site (GlobeNewswire)
Apr-29-25 06:00AM	Aclarion Announces Commercial Agreement with Spine Institute of Louisiana (GlobeNewswire)
Apr-23-25 06:00AM	Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025 (GlobeNewswire)
Apr-21-25 06:00AM	Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis (GlobeNewswire) -11.69%
Apr-09-25 07:00AM	Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub (GlobeNewswire) +9.85%
Apr-02-25 06:00AM	Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California (GlobeNewswire) +11.49%
Mar-31-25 07:00AM	Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives (GlobeNewswire) -10.89%
Mar-26-25 07:00AM	Aclarion Announces Reverse Stock Split (GlobeNewswire) -23.03%
Mar-13-25 09:25AM	Aclarion Provides Shareholder Update (GlobeNewswire) -15.94%
Mar-07-25 09:45AM	Aclarion announces expansion plans with RadNet affiliates in NY, NJ (TipRanks) -13.75%
Mar-06-25 09:35AM	Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey (GlobeNewswire) -77.14%
Mar-03-25 06:00AM	Aclarion Announces First Commercial Agreement with Scripps Health (GlobeNewswire) +126.87%
Feb-28-25 04:01PM	Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders (GlobeNewswire) +27.38%
Feb-20-25 12:31PM	Aclarion, Inc. (ACON) to Showcase NOCISCAN's Impact on Spine Surgery at 2025 Spine Summit (Insider Monkey) +16.85%
06:00AM	Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit (GlobeNewswire)
Feb-11-25 07:58AM	Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body (GlobeNewswire) -10.28%
Feb-06-25 07:23AM	Aclarion Announces Northwestern Medicine as First CLARITY Trial Site (GlobeNewswire)
Feb-04-25 07:23AM	Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded (GlobeNewswire)
Jan-31-25 11:59AM	Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference (GlobeNewswire) -15.48%
Jan-30-25 03:13PM	Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced at the Market (NewMediaWire) -8.82%
Jan-28-25 10:51AM	Aclarion Announces Revised Split Ratio and Timing for Reverse Stock Split (NewMediaWire) -17.02%
Jan-24-25 05:30PM	Aclarion Announces Reverse Stock Split (NewMediaWire) +27.08% -30.42%
Jan-17-25 04:43PM	Aclarion Announces Closing of $14.4 Million Public Offering of Common Stock and Warrants (NewMediaWire) -6.00%
Jan-15-25 09:15AM	Aclarion Announces Pricing of $14.4 Million Public Offering of Common Stock and Warrants (NewMediaWire) -55.64%
Jan-07-25 07:28AM	Aclarion, Inc. Raises Funds Through Stock Offering (TipRanks) -6.70%
Jan-03-25 04:11PM	Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced at the Market (NewMediaWire) +110.14% -42.96%
Dec-03-24 03:45PM	Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing (ACCESS Newswire)
Nov-21-24 08:00AM	Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash (GlobeNewswire)
Nov-14-24 05:00PM	Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st (ACCESSWIRE)
Oct-10-24 07:00AM	Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-27-24 06:57AM	Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes (GlobeNewswire)
Sep-13-24 08:30AM	PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology (GlobeNewswire)
Sep-12-24 06:57AM	Aclarion Provides Corporate Update on Nociscan AI Technology Milestones (GlobeNewswire) +15.38%
06:00AM	Transforming Oncology: Stocks to Watch in the Oncology Sector (News Direct)
Sep-11-24 01:00PM	Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing (ACCESSWIRE)
06:00AM	Aclarion, Inc.'s (NASDAQ: ACON) Emerging Role in the Back Pain Management Sector (News Direct)
Sep-10-24 06:57AM	Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial (GlobeNewswire)
Sep-06-24 11:27AM	Aclarion Added to PRISM Emerging Medical Devices Index (GlobeNewswire)
Sep-05-24 06:57AM	Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market (GlobeNewswire) -6.49%
Aug-29-24 06:57AM	Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey (GlobeNewswire) -5.20%
Aug-21-24 07:57AM	Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans (GlobeNewswire)
Aug-15-24 09:48AM	Aclarion to Present at August 20th Virtual Investor Summit Microcap Event (GlobeNewswire) +10.48%
Aug-14-24 08:08AM	Aclarion Announces First Commercial Agreement in Michigan (GlobeNewswire) -10.27%
Aug-13-24 09:07AM	Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK (GlobeNewswire) -16.98%
Jul-09-24 07:00AM	Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK (GlobeNewswire)
Jun-26-24 08:30AM	Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK (GlobeNewswire) +6.34%
Jun-25-24 08:30AM	Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London (GlobeNewswire)
Jun-20-24 08:00AM	Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution (NewMediaWire)
Jun-18-24 07:00AM	Aclarion Announces Updated Product Release That Enhances User-Experience, Scalability, and Security for Nociscan Solution (NewMediaWire)
May-15-24 10:55PM	ACON Stock Earnings: Aclarion Reported Results for Q1 2024 (InvestorPlace) +17.99%

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Executive ChairmanDr. Jeffrey John Thramann M.D.

CEOMr. Brent Ness

Chief Financial OfficerMr. Gregory A. Gould CPA

Chief Strategy OfficerMr. Ryan Bond

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Breidbart Scott	Director	May 12 '26	Buy	3.18	5,664	18,012	5,664	May 12 06:53 PM
Neal David K	Director	May 11 '26	Buy	3.10	2,500	7,750	2,502	May 12 08:30 AM
Ness Brent	Chief Executive Officer	May 11 '26	Buy	3.18	6,289	19,999	6,300	May 11 04:30 PM
Wesemann William	Director	May 06 '26	Buy	3.30	1,562	5,155	1,563	May 08 05:00 PM
Ness Brent	Chief Executive Officer	Nov 26 '25	Buy	6.20	10	62	11	Dec 01 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

ACON

Aclarion Inc

Upgrade your Finviz experience